These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 15699475)

  • 1. Indifferently pursued or unowned drugs: who should lead where companies do not tread?
    Sausville EA
    J Clin Oncol; 2005 Mar; 23(9):1796-8. PubMed ID: 15699475
    [No Abstract]   [Full Text] [Related]  

  • 2. Staurosporine: new lease of life for parent compound of today's novel and highly successful anti-cancer drugs.
    Ōmura S; Asami Y; Crump A
    J Antibiot (Tokyo); 2018 Aug; 71(8):688-701. PubMed ID: 29934602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The second wave in kinase cancer drugs.
    Garber K
    Nat Biotechnol; 2006 Feb; 24(2):127-30. PubMed ID: 16465146
    [No Abstract]   [Full Text] [Related]  

  • 4. Midostaurin, a Natural Product-Derived Kinase Inhibitor Recently Approved for the Treatment of Hematological Malignancies
    Manley PW; Weisberg E; Sattler M; Griffin JD
    Biochemistry; 2018 Feb; 57(5):477-478. PubMed ID: 29188995
    [No Abstract]   [Full Text] [Related]  

  • 5. 2011 FDA drug approvals.
    Mullard A
    Nat Rev Drug Discov; 2012 Feb; 11(2):91-4. PubMed ID: 22293555
    [No Abstract]   [Full Text] [Related]  

  • 6. Keeping an open mind.
    Nat Rev Drug Discov; 2004 Dec; 3(12):985. PubMed ID: 15645599
    [No Abstract]   [Full Text] [Related]  

  • 7. Non-ATP competitive protein kinase inhibitors as anti-tumor therapeutics.
    Kirkland LO; McInnes C
    Biochem Pharmacol; 2009 May; 77(10):1561-71. PubMed ID: 19167366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment.
    García-Echeverría C
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4308-12. PubMed ID: 20561789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Midostaurin (Rydapt) for AML and advanced systemic mastocytosis.
    Med Lett Drugs Ther; 2017 Aug; 59(1527):e140. PubMed ID: 28787746
    [No Abstract]   [Full Text] [Related]  

  • 10. Introduction: targeting different pathways to prevent tumor cell development.
    Kantarjian HM
    Semin Oncol; 2009 Apr; 36(2 Suppl 1):S1-5. PubMed ID: 19393830
    [No Abstract]   [Full Text] [Related]  

  • 11. [Tyrosine kinases as targets of cancer therapy: from disbelief to Lazarus responses].
    Joensuu H
    Duodecim; 2012; 128(21):2261-8. PubMed ID: 23210289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combinations of 5-fluorouracil with UCN-01 or staurosporine.
    Sigmond J; Comijn EM; Kamphuis JA; Peters GJ
    Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1503-6. PubMed ID: 15571286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population differences in the use of EGFR-targeted agents.
    Saijo N
    Clin Adv Hematol Oncol; 2008 Oct; 6(10):730-2. PubMed ID: 18997662
    [No Abstract]   [Full Text] [Related]  

  • 14. [Individualisation and "orphanization" in oncology].
    Schenk M
    Dtsch Med Wochenschr; 2011 Apr; 136 Suppl 1():S27-30. PubMed ID: 21452104
    [No Abstract]   [Full Text] [Related]  

  • 15. Midostaurin in patients with indolent systemic mastocytosis: An open-label phase 2 trial.
    van Anrooij B; Oude Elberink JNG; Span LFR; de Monchy JGR; Rosati S; Mulder AB; Kluin-Nelemans JC
    J Allergy Clin Immunol; 2018 Sep; 142(3):1006-1008.e7. PubMed ID: 29890238
    [No Abstract]   [Full Text] [Related]  

  • 16. Comprehensive review of kinase inhibitor therapy that is long overdue for oncologists. Foreword.
    McMullen KP
    Curr Probl Cancer; 2013; 37(3):109. PubMed ID: 23972981
    [No Abstract]   [Full Text] [Related]  

  • 17. Acquired resistance to tyrosine kinase inhibitors during cancer therapy.
    Engelman JA; Settleman J
    Curr Opin Genet Dev; 2008 Feb; 18(1):73-9. PubMed ID: 18325754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and development of aurora kinase inhibitors as anticancer agents.
    Pollard JR; Mortimore M
    J Med Chem; 2009 May; 52(9):2629-51. PubMed ID: 19320489
    [No Abstract]   [Full Text] [Related]  

  • 19. PI3K and mTOR inhibitors: a new generation of targeted anticancer agents.
    Brachmann S; Fritsch C; Maira SM; García-Echeverría C
    Curr Opin Cell Biol; 2009 Apr; 21(2):194-8. PubMed ID: 19201591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Protein tyrosine kinase inhibitors in cancer therapy].
    Boutayeb S; Zakkouri FZ; Aitelhaj M; Mesmoudi M; Boutayeb A; Boutayeb W; Mrabti H; Errihani H
    Pathol Biol (Paris); 2012 Aug; 60(4):229-33. PubMed ID: 22743095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.